James E Deerfield Mgmt L.P.... Net Worth

The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $623 Thousand dollars as of 22 September 2015. James P owns over 175,000 units of Regenxbio Inc stock worth over $622,790 and over the last 9 years James sold RGNX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James P RGNX stock SEC Form 4 insiders trading

James has made over 1 trades of the Regenxbio Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James bought 175,000 units of RGNX stock worth $3,850,000 on 22 September 2015.

The largest trade James's ever made was buying 175,000 units of Regenxbio Inc stock on 22 September 2015 worth over $3,850,000. On average, James trades about 175,000 units every 0 days since 2015. As of 22 September 2015 James still owns at least 49,000 units of Regenxbio Inc stock.

You can see the complete history of James P stock trades at the bottom of the page.

Insiders trading at Regenxbio Inc

Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.

What does Regenxbio Inc do?

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.

Complete history of James P stock trades at Regenxbio Inc

Regenxbio Inc executives and stock owners

Regenxbio Inc executives and other stock owners filed with the SEC include:

• Kenneth Mills,
  President, Chief Executive Officer, Executive Director
• Steve Pakola,
  Senior Vice President, Chief Medical Officer
• Vittal Vasista,
  Chief Financial Officer, Senior Vice President
• Olivier Danos,
  Senior Vice President, Chief Scientific Officer
• Curran Simpson,
  Senior Vice President - Product Development, Chief Technology Officer
• Kenneth T. Mills,
  Pres, CEO & Director
• Vittal K. Vasista,
  Chief Financial Officer
• Dr. Olivier Danos Ph.D.,
  Chief Scientific Officer
• Curran M. Simpson M.S.,
  Chief Operations & Technology Officer
• Patrick J. Christmas II, J.D.,
  Chief Legal Officer
• Patrick J. Christmas II,
  Chief Legal Officer
• Dr. Stephen Pakola,
  Chief Medical Officer
• Luke Beshar,
  Independent Director
• David Stump,
  Independent Director
• Daniel Abdun-Nabi,
  Independent Director
• A. N. Karabelas,
  Lead Independent Director
• Daniel Tasse,
  Independent Director
• Alexandra Glucksmann,
  Independent Director
• Allan Fox,
  Chairman of the Board
• Dr. Laura A. Coruzzi J.D., Ph.D.,
  Sr. VP of Intellectual Property
• Ram Palanki,
  Sr. VP of Commercial Strategy & Operations
• Dr. Laura A. Coruzzi,
  Sr. VP of Intellectual Property
• Shiva G. Fritsch,
  Chief People Officer
• Andrew Yost,
  VP of Corp. Devel.
• Tricia Truehart,
  VP of Investor Relations & Corp. Communications
• Stephen Yoo,
  Chief Medical Officer
• Llc Fmr,
  10% owner
• Camille D Samuels,
  Director
• Faraz Ali,
  Chief Business Officer
• Edgar Engleman,
  Director
• James E Deerfield Mgmt L.P....,
  
• Donald J Jr Hayden,
  
• Patrick J. Christmas,
  Chief Legal Officer
• Jean Bennett,
  
• George V Migausky,
  
• Jennifer Zachary,